Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
151 hedge funds and large institutions have $660M invested in Eagle Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 63 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more capital invested
Capital invested by funds: $516M → $660M (+$143M)
3% more funds holding
Funds holding: 146 → 151 (+5)
32% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.13M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.66M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$4.43M |
| 4 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
+$2.66M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.2M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.51M |
| 3 |
Goldman Sachs
New York
|
-$4.46M |
| 4 |
Millennium Management
New York
|
-$2.62M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$2.15M |
EGRX Hedge Fund Activity: Q3 2021 in Review
151 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2021, worth a combined $660M — up 28% from $516M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new EGRX positions and 9 closed out — a net gain of 6 holders — while 43 added to existing stakes and 63 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $8.13M. The largest seller was Invesco, cutting an estimated $12.2M.
- 151 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2021, up from 146 in Q2 2021.
- Funds reported $660M of Eagle Pharmaceuticals, Inc. stock for Q3 2021, up 28% quarter-over-quarter.
- 15 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2021 and 9 closed out, a net change of +6 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2021 was Balyasny Asset Management, an estimated $8.13M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2021 was Invesco, an estimated $12.2M sold.
Based on aggregated 13F filings for Q3 2021.